Application of polyketone natural product compound in resisting coxsackie virus B3
Through the application of polyketone natural product compounds (3S, 4S)-Sclerotinin A and Ligustrone B, the problem of lack of effective treatment methods for Coxsackie virus type B3 infection was solved, and the inhibitory activity on CVB3 was achieved, and it has the potential to become clinically Effective anti-CVB3 infection drugs, and the extraction process is simple and easy to produce on a large scale.
Patent Information
- Application Number
- CN202410992176.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-23
- Publication Date
- 2024-12-03
- Estimated Expiration
- 2044-07-23
Smart Images

Figure CN119055635A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to the technical field of antiviral drugs, and in particular to the application of two polyketide natural product compounds (3S, 4S)-Sclerotinin A and Ligustrone B in resisting CVB3 virus. Background Art
[0002] Coxsackievirus is a member of the Enterovirus genus of Picornaviridae. Its infection can cause a variety of diseases, such as hand, foot and mouth disease, aseptic meningitis, encephalitis, myocarditis, epidemic myositis, herpetic pharyngitis, etc. There are 29 reported CV serotypes. According to their pathogenic characteristics to suckling mice and their different sensitivity to cells, they can be divided into two groups, A and B, namely CVA (CVA1-22, 24) and CVB (CVB1-6). Infection with CVBs is the most common, among which CVB3 is the most pathogenic type among the six serotypes of CVB and is the main cause of viral myocarditis. According to statistics from the Centers for Disease Control and Prevention (CDC), CVB (types 1-6) can cause about 5 million people to suffer from intestinal system diseases each year, of which 10%-20% are acute myocarditis caused by CVB3. In recent years, the trend of CVB3 causing hand, foot and mouth disease has also been on the rise, and there have been many reports of CVB3-induced disease epidemics in my country. At present, there is no specific drug for Coxsackie virus infection, and there is no targeted treatment in clinical practice. Many researchers have found many compounds that have the ability to inhibit CVB3 activity in vivo and in vitro, but these are still in the early stages of laboratory experiments and are still far from practical clinical application. Therefore, it is imperative to develop specific and effective anti-CVB3 drugs.
[0003] Polyketides are a class of secondary metabolites produced by plants or microorganisms. They are widely found in nature, and tens of thousands of species have been discovered so far. Polyketides have complex structures and have a variety of biological activities, including antibacterial, anti-tumor and antioxidant activities. They are widely used in agriculture, food industry and health care. (3S,4S)-Sclerotinin A is a natural product of isocoumarins. It was first isolated from Penicillium citrinum ( Penicillium citrinum ) and Sclerotinia sclerotiorum ( Sclerotinia Sclerotiorum). As a plant growth regulator, (3S,4S)-Sclerotinin A can promote the growth of rice seedlings at a concentration of 5 ppm (Curtis et al. J. Chem. Soc C.1968, 85-93; Sassa et al. Agric. Biol. Chem. 1968, 32, 1432-1439). Ngan et al. found that (3S,4S)-Sclerotinin A has almost no anti-inflammatory activity (Ngan et al. Arch. Pharm. Res.2017, 40, 328-337). Ligustrone B is a rare fungal metabolite that contains chromone and indone structures in its skeleton. As the main product of the plant pathogen Cercospora ligustrina, the biological activity of Ligustrone B has been rarely reported (Arnone et al. Gazz. Chim. Ital. 1975, 105, 1093).
[0004] We evaluated the inhibitory activity of polyketide natural product compounds (3S,4S)-Sclerotinin A and Ligustrone B against CVB3 virus. Summary of the invention
[0005] The purpose of the present invention is to provide a polyketide natural product compound for use in resisting Coxsackievirus B3 type in view of the above situation.
[0006] The polyketide compounds include (3S, 4S)-Sclerotinin A and Ligustrone B.
[0007] The chemical structure of the (3S, 4S)-Sclerotinin A is shown in formula (I): Formula (I).
[0008] The chemical structure of Ligustrone B is shown in formula (II): Formula (II).
[0009] The purpose of the present invention is achieved by testing the activity of polyketide natural product compounds (3S, 4S)-Sclerotinin A and Ligustrone B by combining cytopathic effect (CPE) inhibition analysis with MTT method to determine cell viability.
[0010] Through a large number of biological experiments, the applicant found that compounds (3S, 4S)-Sclerotinin A and Ligustrone B have anti-CVB3 virus activity, which can strongly inhibit the cytopathic effect caused by CVB3 virus and enhance the survival rate of infected cells. They can strongly inhibit the replication and proliferation of CVB3 virus in cells and reduce the production of progeny viruses. This shows that compounds (3S, 4S)-Sclerotinin A and Ligustrone B have the potential to prepare specific therapeutic drugs for anti-CVB3 infection and have great clinical application prospects.
[0011] The present invention has the following advantages: 1. The extraction process of these compounds is simple, economical and fast, and easy to promote large-scale production.
[0012] 2. The antiviral activity of compounds (3S,4S)-Sclerotinin A and Ligustrone B has not been reported, which has a certain guiding role in the development of their anti-CVB3 viral activity.
[0013] 3. It is easy to find anti-CVB3 drugs from compounds with similar structures through structure-activity relationship research to find their targets, which provides certain reference significance for further drug development. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 The effects of polyketide natural product compounds (3S,4S)-Sclerotinin A and Ligustrone B on the survival rate of Hep-2 cells treated with CVB3.
[0015] Figure 2 The polyketide natural product compounds (3S,4S)-Sclerotinin A and Ligustrone B have an inhibitory effect on CVB3-induced CPE in Hep-2 cells.
[0016] Figure 3 The inhibitory effects of polyketide natural product compounds (3S,4S)-Sclerotinin A and Ligustrone B on the production of CVB3 progeny virus. DETAILED DESCRIPTION
[0017] The polyketide natural product compounds (3S, 4S)-Sclerotinin A and Ligustrone B used in the present invention are separated from the rice solid fermentation product of Talaromyces funiculosus R5SSF2.
[0018] The invention relates to application of polyketide-containing natural product compounds (3S, 4S)-Sclerotinin A and Ligustrone B in preparing anti-CVB3 virus drugs.
[0019] The application refers to a preparation containing (3S, 4S)-Sclerotinin A and Ligustrone B and added with pharmaceutically acceptable excipients and carriers for preparing an anti-CVB3 virus preparation.
[0020] The preparation is granules, tablets, pills, capsules, injections or dispersions.
[0021] The (3S, 4S)-Sclerotinin A of the present invention has a chemical structural formula shown in formula (I): Formula (I).
[0022] Ligustrone B of the present invention has a chemical structural formula shown in formula (II): Formula (II).
[0023] The present invention contains compounds (3S, 4S)-Sclerotinin A and Ligustrone B as anti-CVB3 virus applications, including the series of compounds that strongly inhibit the cytopathic effect (CPE) produced by CVB3 in host cells Hep-2 and enhance cell survival. They strongly inhibit the replication and proliferation of CVB3 viruses in cells and reduce the production of progeny viruses. These studies indicate that the series of compounds have the potential to be further developed into drugs that effectively treat CVB3 infection.
[0024] The applicant has conducted an anti-CVB3 activity study experiment on the above compounds, and the experimental results are as follows: In the following, unless otherwise specified, the materials and operating methods used in the present invention are well known in the art.
[0025] 1. Test content: Analysis of compound anti-CVB3 activity: The present invention combines cytopathic effect analysis and MTT cell viability assay to evaluate the anti-CVB3 activity of compounds (3S, 4S)-Sclerotinin A and Ligustrone B.
[0026] 2. Test methods: 2.1.1 Toxicity of compounds to host Hep-2 cells Hep-2 cells were plated in 96-well plates and cultured in a 37°C, 5% CO2 incubator until the cells grew to a monolayer. The cell culture medium was discarded and cell maintenance medium containing different concentrations of the test compound was added to continue the culture. After 48 h, the cytotoxicity was observed and recorded under a microscope. The cell survival rate was determined by the MTT method. SPSS 11.5 software was used to calculate the median cytotoxic concentration (CC) of the drug for cells. 50 ). Cell survival rate = (mean OD of drug group 492 Value / average OD of cell control group 492 value) × 100%.
[0027] 2.1.2 Inhibitory activity of compounds against CVB3 Hep-2 cells were plated in 96-well plates and cultured in a 37°C, 5% CO2 incubator until the cells grew to a monolayer. The culture medium was discarded and 100 TCID 50 The cells were infected with CVB3 virus solution for 1 hour, and different concentrations of test compounds (ribavirin as a positive control drug) were added to incubate the cells. After continuing to culture for about 48 hours, when about 90% CPE lesions appeared in the virus control wells, the cytopathic effect (CPE) was observed under a microscope. The observation and recording method of CPE: no cytopathic effect is recorded as -, 25% or less cytopathic effect is recorded as +, 25%-50% cytopathic effect is recorded as ++, 50%-75% cytopathic effect is recorded as +++, and 75% or more cytopathic effect is recorded as +++.
[0028] After the CPE observation was completed, the MTT method was used to detect the inhibition rate of the drug on CVB3. The specific steps were as follows: 50 μL (5 mg·mL-1) of MTT was added to each well, the supernatant was removed after incubation for 3-4 h, and an equal volume of DMSO was added to dissolve the precipitate. The corresponding absorbance (OD 492 The inhibitory rate of the drug on CVB3 was calculated using the following formula. The half effective concentration (EC) of the drug was calculated using SPSS 11.5 software. 50 ).
[0029]
[0030] 2.1.3 Therapeutic Index (SI) of Drugs SI = CC 50 / EC 50 The higher the therapeutic index, the greater the antiviral potential.
[0031] 3. Test results Table 1 Toxicity of (3S,4S)-Sclerotinin A and Ligustrone B to Hep-2 cells and their anti-CVB3 activity
[0032] The results of the compound cytotoxicity and anti-CVB3 activity tests are shown in Table 1. The concentration-dependent effects of the compounds on the survival rate of Hep-2 cells acted with CVB3 are shown in Table 1. Figure 1 As shown. The present invention detected that (3S, 4S)-Sclerotinin A and Ligustrone B have certain inhibitory activity against CVB3, and the therapeutic index is improved. The experimental results have a certain guiding role in suggesting the development of more efficient and low-toxic anti-CVB3 drugs through structural modification.
[0033] Compounds (3S,4S)-Sclerotinin A and Ligustrone B inhibited CVB3-induced CPE in Hep-2 cells. Figure 2 As shown in the figure. Hep-2 cells infected with CVB3 became round and separated from the cell wall. Hep-2 cells treated with (3S,4S)-Sclerotinin A at 200μM / mL and Ligustrone B at 200μM / mL grew well, almost close to the morphological characteristics of the control group of cells without virus infection. This shows that these two compounds have a good inhibitory effect on the cell pathological changes caused by CVB3 infection. The applicant has conducted in-depth research on the anti-CVB3 activity of compounds (3S, 4S)-Sclerotinin A and Ligustrone B, and conducted tests on the inhibitory effects of (3S, 4S)-Sclerotinin A and Ligustrone B on the production of CVB3 progeny viruses. The test results are as follows: 1. Test content The inhibitory effects of (3S,4S)-Sclerotinin A and Ligustrone B on the production of CVB3 progeny viruses were detected after CVB3 infected Hep-2 cells.
[0034] 2. Test methods Hep-2 cells in logarithmic growth phase were plated in 24-well plates. After confluent monolayers, 100 TCID 50 The cells were infected with CVB3 and incubated at 37°C for 1.5 h. The virus solution was removed and the cells were washed three times with PBS. Cell maintenance medium containing 200 μM / mL (3S, 4S)-Sclerotinin A and 200 μM / mL Ligustrone B was added. The cells and supernatant culture medium were collected at 12 h and 36 h, respectively, and lysed by freezing and thawing at -20°C and 37°C for three times. The TCID50 Methods The CVB3 virus titer was determined.
[0035] 3. Test results like Figure 2 As shown, the cell survival rate of Hep-2 cells infected with CVB3 treated with (3S,4S)-Sclerotinin A and Ligustrone B was significantly increased compared with the virus control group, indicating that the above compounds can significantly inhibit the activity of CVB3.
[0036] like Figure 3 As shown, the virus titers of Hep-2 cells treated with compounds (3S, 4S)-Sclerotinin A and Ligustrone B were significantly reduced compared with the virus control group, which were reduced by 3.5 log and 4.4 log respectively. They showed a very strong inhibitory effect, indicating that these compounds can strongly inhibit the replication and proliferation of viruses in cells.
[0037] In summary, the polyketide natural product compounds (3S,4S)-Sclerotinin A and Ligustrone B have strong inhibitory activity against CVB3, including inhibiting the Hep-2 cell cytopathic effect caused by CVB3 virus, significantly reducing the production of progeny viruses, and having a high therapeutic index. This indicates that the compounds have the potential to be used in the preparation of clinically effective drugs against CVB3 infection.
Claims
1. A polyketide natural product compound is used in an anti-CVB3 virus drug, wherein the polyketide compound comprises (3S, 4S)-Sclerotinin A and Ligustrone B; The chemical structure of the (3S, 4S)-Sclerotinin A is shown in formula (I): Formula (I); The chemical structure of Ligustrone B is shown in formula (II): Formula (II).
2. The use of the polyketide natural product compound according to claim 1 in an anti-CVB3 virus drug, characterized in that: The polyketide natural product compounds (3S, 4S)-Sclerotinin A and Ligustrone B have anti-CVB3 virus activity.
3. The use of the polyketide natural product compound in anti-CVB3 virus according to claim 2, characterized in that: The polyketide compound (3S, 4S)-Sclerotinin A has an inhibition rate of 88% for CVB3 at 200 μM / mL; and the inhibition rate of Ligustrone B has an inhibition rate of 92% for CVB3 at 200 μM / mL.
4. The use of the polyketide natural product compound in anti-CVB3 virus according to claim 3, characterized in that: The polyketide natural product compounds (3S, 4S)-Sclerotinin A and Ligustrone B are used as CVB3 virus inhibitors, and pharmaceutically acceptable excipients and carriers are added to prepare anti-CVB3 virus preparations.
5. The use of the polyketide natural product compound in anti-CVB3 virus according to claim 4, characterized in that: The preparation is any one of granules, tablets, pills, capsules, injections or dispersions.
Citation Information
Patent Citations
Application of polyketone compound in preparation of anti-coronavirus medicine
CN116036071A
Host Cell Kinases as Targets for Antiviral Therapies Against HCV Infection
US20110229484A1
Muscodor albus Strain Producing Volatile Organic Compounds and Methods of Use
US20140086878A1
Preparation and application of polyketone compound having Anti-novel coronavirus activity
WO2022246810A1
IN4529CHN2012A
